2.Novo’s Older GLP-1 Drug Slows Cognitive Decline in Phase IIb Alzheimer’s Trial.July 30, 2024.Nick Paul Taylor 3.Novo's GLP-1 liraglutide may protect brain from Alzheimer's, new study finds.By Darren Incorvaia Jul 30, ...
最新的抗肥胖药物靶向glp-1受体,胰高血糖素样肽-1 受体 (glp1r) 是一种在胰腺 β 细胞和大脑神经元上发现的受体蛋白,它通过增强胰岛素分泌参与控制血糖水平。 胰高血糖素样肽1受体激动剂(glp-1 receptor agonists, 简称glp-1肽),通过增强β胰腺细胞分泌胰岛素...
[2]Matza LS, Curtis SE, Jordan JB, et al. Physician perceptions of GLP-1 receptor agonists in the UK[J]. Curr Med Res Opin, 2016, 32(5): 857-864. [3]Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides[J]. Natur...
[27] Luli, Alex, et al. "Barriers to Obtaining GLP-1 Receptor Agonists and SGLT2 Inhibitors in a Free Clinic Population With Type 2 Diabetes and Cardiovascular Disease." Journal of Contemporary Pharmacy Practice 70.1 (2023): 9-13.[28] Mahtta, Dhruv, et al. "Utilization rates of SGLT2...
新型的糖尿病治疗药物GLP-1受体激动剂,又迎来一个里程碑时刻。 近日,由Aditi R. Saxena领衔的研究团队,在著名期刊《自然·医学》发表全球首个口服小分子GLP-1受体激动剂(danuglipron)的重要临床研究数据[1]。 研究结果表明, danuglipron能显著降低2型糖尿病(T2DM)患者空腹血糖、餐后血糖及HbA1c水平,同时减轻...
胰高糖素样肽-1(GLP-1)是一种内源性肠促胰岛素分泌剂,在维持人体血糖稳定中发挥重要作用。胰高糖素样肽-1受体激动剂(glucagon-likepeptide-1receptoragonists,GLP-1RA)属于肠促胰素类药物,对GLP-1生理作用的研究显示,其不仅可增强β细胞反应,还能通过作用于α细胞减少胰高血糖素分泌,进而减少肝糖输出,以及作用于...
10月5日,JAMA上发表了研究《Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss》。表明使用GLP-1激动剂可能会增加胰腺炎、肠梗阻和胃轻瘫的风险。 此前已有研究表明,糖尿病患者发生胃肠道(胆道疾病、胰腺炎、肠梗阻和胃痉挛)的风险增加。由于糖尿病...
5 Bea S, Son H, Bae JH, Cho SW, Shin JY, Cho YM. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study. Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom...
胰高血糖素样肽1受体激动剂(GLP-1 receptor agonists, 简称GLP-1肽),通过增强β胰腺细胞分泌胰岛素和抑制α胰腺细胞释放胰高血糖素来改善血糖控制。[5] 此外,激动剂会减缓胃排空、增加饱腹感并降低食欲 ,导致体重减轻。GLP-1肽可以分为短效或长效药物。[6] ...
S. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's & dementia (New York, N. Y.), 8(1), e12268. doi.org/10.1002/trc2.12 [4...